Kintara Therapeutics Announces Fiscal 2022 First Quarter Financial Results and Provides Corporate Update November 15, 2021 • 8:15 AM EST
Kintara Therapeutics to Present at the Q4 Investor Summit Virtual Conference on November 17, 2021 November 11, 2021 • 8:30 AM EST
Kintara Therapeutics Announces Fiscal Year 2021 Financial Results and Provides Corporate Update September 29, 2021 • 8:00 AM EDT
Kintara Announces Closing of $15.0 million Offering Priced at a Premium to Market September 28, 2021 • 1:33 PM EDT
Kintara Announces $15.0 million Offering of Common Stock and Warrants Priced at a Premium to Market September 24, 2021 • 8:00 AM EDT
Kintara Reports Topline Results from Phase 2 Clinical Study of VAL-083 as Adjuvant Therapy for Newly-Diagnosed GBM Patients September 22, 2021 • 8:00 AM EDT
Kintara Therapeutics Provides Positive Site Activation Update on GCAR Phase 2/3 Clinical Trial for Glioblastoma August 17, 2021 • 8:00 AM EDT
Kintara Therapeutics to Present at the Investor Summit Virtual Conference on August 17, 2021 August 12, 2021 • 8:00 AM EDT